All enrolled people who gained not less than just one dose of zosuquidar or placebo during induction ended up monitored for that event of adverse activities (439 patients, 219 on zosuquidar and 210 on placebo). The commonest adverse activities ended up connected with the period of prolonged and substantial myelosuppression https://tiflucarbine34679.blogofchange.com/28552677/facts-about-bms-199264-hydrochloride-revealed